Skeletal Muscle Inflammation, Oxidative Stress and DNA Repair in Age-Related Sarcopenia

NCT02116166 | Completed DMC

• 2 other identifiers: 201300790-N2P30AG028740
• Study Type: observational
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to investigate how and why the loss of muscle mass occurs with aging. Tissue collected from young subjects will be compared to previously collected tissue from elderly subjects, as well as previously collected data on muscle function/mass to further investigate cellular and molecular pathways that have recently been shown to be important for the aging process in muscle. The Principal Investigator (PI) and the study team will look for specific proteins (called biomarkers) that can be present in the muscle tissue in various amounts in different individuals. This study will increase the investigators understanding of the processes of muscle atrophy (loss of mass) and functional loss at older age and will help to find new treatments and interventions aimed at improving the quality of life and independence of America's rapidly expanding elderly population.

Conditions

Sarcopenia

Keywords

aging; sarcopenia; mitochondria; skeletal muscle; inflammation

Outcome Measures

Primary Outcomes (14)

• Tumor Necrosis Factor alpha (TNF-alpha)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• tumor-necrosis factor receptor-1 (TNFR1)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• Phospho-Inhibitory Subunit Of NF-KBα (pIkBα)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• Chemokine (C-C motif) ligand 2 (CCL2)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• zinc transporter (ZIP) 14

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• Interleukin 6 (IL-6)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• Interleukin (IL) 11β

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• Interleukin 8 (IL-8)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• C-C chemokine receptor type 2 (CCR2)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• zinc transporter 14 (ZIP14)

  Inflammation marker; measured in muscle biopsy specimens.

  baseline

• copper

  metals; measured in muscle biopsy specimens.

  baseline

• zinc

  metals; measured in muscle biopsy specimens.

  baseline

• iron

  metals; measured in muscle biopsy specimens.

  baseline

• ribosome profiling

  DNA damage on pattern and dynamics of mRNA translation in human muscle tissue; measured in muscle biopsy specimens.

  baseline

Study Arms (2)

Young

Young (20-35 years old)

Old

Older (70-99 years old)

Eligibility Criteria

• Age: 20 Years - 35 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

Young (age 20-35 years; N =10)

You may qualify if:

• males and females aged 20-35.
• willing and able to give informed consent.

You may not qualify if:

• High physical activity level (i.e., the subject has spent greater than 300 minutes per week in the past 2 month performing structured physical activity, such as exercising at a gym and/or weight training)
• Active treatment for cancer or history of cancer in the past 3 years
• Congestive heart failure NYHA Class III or IV
• Previous stroke with upper and/or lower extremities involvement within the last 6 months
• Peripheral vascular disease Fontaine Class III/IV
• History of life-threatening cardiac arrhythmias, stroke, severe Parkinson's disease or severe neurological disorders likely to interfere with physical function
• Renal disease requiring dialysis
• Lung disease requiring steroids
• Lower extremity amputation
• Complicated diabetes
• Life-threatening illnesses with an estimated life expectancy less than 1 year
• Anticoagulant therapy (aspirin use is allowed, but participants will be asked to stop taking it 48 hours prior to muscle biopsy)
• Involved in active weight loss \> 5 kg in prior 3 months
• Pregnancy (determined by a pregnancy test)
• Lidocaine allergy

Sponsors & Collaborators

• University of Florida: lead
• National Institute on Aging (NIA): collaborator

Study Sites (1)

University of Florida

Gainesville, Florida, 32611, United States

Location

Related Links

• University of Florida Claude D. Pepper Older Americans Independence Center (OAIC)

Biospecimen

Retention: SAMPLES WITH DNA

Skeletal muscle biopsy

MeSH Terms

Conditions

Sarcopenia; Inflammation

Condition Hierarchy (Ancestors)

Muscular Atrophy; Neuromuscular Manifestations; Neurologic Manifestations; Nervous System Diseases; Atrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Pathologic Processes

Study Officials

• Christiaan Leeuwenburgh, PhD

  University of Florida

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 14, 2014
• First Posted: April 16, 2014
• Study Start: May 1, 2014
• Primary Completion: July 1, 2016
• Study Completion: July 1, 2016
• Last Updated: April 5, 2018

Record last verified: 2018-04

Locations

US (1)